Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
A new Covid drug designed to reduce the risk of vulnerable patients needing hospital treatment will be available on the NHS from today.
Sotrovimab is a monoclonal antibody given as a transfusion to transplant recipients, cancer patients and other high-risk groups.
If given quickly after symptoms develop it is should help prevent people from falling seriously ill with the disease.
Initial tests suggest it should still work against the Omicron variant.
"These new drugs have an important role to play," said Prof Steven Powis, the national medical director of NHS England.
"If you test positive and are at high risk then we will be contacting you, and, if eligible, you will be able to get access to these new treatments."
Defo TR, initially they made 2.4m doses which is charged out at $2100, GSK & Vir are ramping up the next production run which could be 10m plus especially now it is a intramuscular jab as opposed to the original version being intravenous which is much more time & labour intensive.
Preclinical Data Highlight the Significant Antigenic Shift of the Omicron SARS-CoV-2 Variant and its Effect on the Neutralizing Activity of Monoclonal Antibodies, Convalescent Antibodies and Vaccine-Elicited Antibodies
12/14/21 at 4:39 PM EST
PDF Version
– Data demonstrate sotrovimab, developed by Vir in conjunction with GlaxoSmithKline, continues to retain in vitro neutralizing activity against all tested variants of concern, including Omicron –
SAN FRANCISCO, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new preclinical data, published to the preprint server bioRxiv, demonstrating the impact of the significant antigenic shift of the new SARS-CoV-2 Omicron variant (B.1.1.529). A significant reduction in plasma neutralizing activity
Glaxo confirmed that their monoclonal antibody treatment works against all mutations of Omicron.
And a further contract has been signed to supply Singapore.
TR64 was ahead of the game on this one.
Daily Mail reports that the success of GSK/Vir’s monoclonal antibody Sotrovimab against Omicron is a ‘shot in the arm’ for Walmsley,.
Vir is being mooted as a takeover target for Glaxo who currently own 8/10% of Vir’s stock.
Sotrovimab GSK/Vir’s Covid monoclonal antibody is the only treatment that remains effective against the New strain of Covid19, Vir is up 15% pre-market Nasdaq.
GSK owns 8/10% of Vir Biotechnology.
Needham’s have just raised the Vir pt from $135 to $200.
Great article on ‘Seeking Alpha’ about Glaxo/Vir’s monoclonal antibody therapy Sotrovimab, it’s saying it has stood up to all mutations so far, whilst vaccines are going to take up to three months to modify & a lot longer manufacture & deliver.
Vir Biotechnology trades on the Nasdaq and SAlpha believes it could shoot up.
Vir Biotechnology was up 12% today after Merck’s Covid drug was found to have only 30% efficacy in the latest trials, Glaxo/Vir’s antibody therapy Sotrovimab/Xevudy stands up against the latest mutation with 85% efficacy.